Acute Adverse Events of Intravesical Bacillus Calmette-Guérin Induction in Non-Muscle-Invasive Bladder Cancer: A Prospective Observational Study From a Tertiary Care Centre in South India

Introduction Intravesical bacillus Calmette-Guérin (BCG) is the standard adjuvant treatment for intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC), but its adverse events can limit tolerability. Prospective data on the acute adverse events of BCG induction in Indian practice are limited. We describe the acute adverse events of BCG induction at a tertiary care centre in South India. Methods In this prospective observational study, 29 consecutive patients with histologically confirmed NMIBC received a six-week induction course of intravesical BCG (120 mg weekly) after complete transurethral resection between December 2023 and February 2025. Patients were assessed at each weekly instillation and for one month after the last instillation. Adverse events were classified as local or systemic, and proportions are reported with exact 95% confidence intervals (CIs). Results The median age was 67 years (interquartile range 52-73), and 25 patients (86.2%) were male. Adverse events occurred in 17/29 (58.6%) patients (95% CI 38.9-76.5). Local events occurred in 12 patients (41.4%): cystitis in 10 (34.5%), hematuria in one (3.4%), and epididymo-orchitis in one (3.4%). Systemic events occurred in five patients (17.2%), all of which were fever below 38.5°C. In 16 of the 17 affected patients (94.1%), the adverse event began within 48 hours of an instillation. No patient required hospital admission or interruption of BCG therapy (0/29, 0%; 95% CI 0-11.9), and no baseline characteristic was significantly associated with adverse events. Conclusions In this small cohort treated with 120-mg Russia (Moscow) strain BCG, acute adverse events during induction were common, predominantly local and began early after instillation, and none led to hospital admission or interruption of treatment. These findings support outpatient induction with early symptom review after each instillation, but this sample cannot exclude uncommon serious complications; larger studies with standardised grading and follow-up through maintenance are needed.

Authors

Publication Details

Journal
Cureus
Published
2026-11-19
DOI
https://doi.org/10.7759/cureus.119927
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Acute Adverse Events of Intravesical Bacillus Calmette-Guérin Induction in Non-Muscle-Invasive Bladder Cancer: A Prospective Observational Study From a Tertiary Care Centre in South India

Anil Kumar Nallabothula, Kasi Viswanath Gali, Naveen Kumar Yadlapalli, Lakshmi Prasanna Karanam et al.
Cureus
Bladder and Urothelial Cancer Treatments
article

Acute Adverse Events of Intravesical Bacillus Calmette-Guérin Induction in Non-Muscle-Invasive Bladder Cancer: A Prospective Observational Study From a Tertiary Care Centre in South India

Anil Kumar Nallabothula, Kasi Viswanath Gali, Naveen Kumar Yadlapalli, Lakshmi Prasanna Karanam, Sree Gouri Sivaram Rajappagari, Karthik Kumar Kosuri, Bharath Kumar Nandavaram, Dheeraj Kumar Kuruva
article en

Abstract

Introduction Intravesical bacillus Calmette-Guérin (BCG) is the standard adjuvant treatment for intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC), but its adverse events can limit tolerability. Prospective data on the acute adverse events of BCG induction in Indian practice are limited. We describe the acute adverse events of BCG induction at a tertiary care centre in South India. Methods In this prospective observational study, 29 consecutive patients with histologically confirmed NMIBC received a six-week induction course of intravesical BCG (120 mg weekly) after complete transurethral resection between December 2023 and February 2025. Patients were assessed at each weekly instillation and for one month after the last instillation. Adverse events were classified as local or systemic, and proportions are reported with exact 95% confidence intervals (CIs). Results The median age was 67 years (interquartile range 52-73), and 25 patients (86.2%) were male. Adverse events occurred in 17/29 (58.6%) patients (95% CI 38.9-76.5). Local events occurred in 12 patients (41.4%): cystitis in 10 (34.5%), hematuria in one (3.4%), and epididymo-orchitis in one (3.4%). Systemic events occurred in five patients (17.2%), all of which were fever below 38.5°C. In 16 of the 17 affected patients (94.1%), the adverse event began within 48 hours of an instillation. No patient required hospital admission or interruption of BCG therapy (0/29, 0%; 95% CI 0-11.9), and no baseline characteristic was significantly associated with adverse events. Conclusions In this small cohort treated with 120-mg Russia (Moscow) strain BCG, acute adverse events during induction were common, predominantly local and began early after instillation, and none led to hospital admission or interruption of treatment. These findings support outpatient induction with early symptom review after each instillation, but this sample cannot exclude uncommon serious complications; larger studies with standardised grading and follow-up through maintenance are needed.

Cureus
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon